Investor Relations


Investor Relations

Corporate Profile

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

Our investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.

We have initiated Phase 2 studies in two target indications: myasthenia gravis (MG) and Thyroid Eye Disease (TED). We submitted an IND in one additional indication, warm autoimmune hemolytic anemia (WAIHA), in November 2019. We plan to continue expanding our pipeline with innovative therapies that could transform the lives of patients living with autoimmune diseases.

Data Provided by Refinitiv. Minimum 15 minutes delayed.